Financial Comparison: Bavarian Nordic A/S (OTCMKTS:BVNRY) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Bavarian Nordic A/S (OTCMKTS:BVNRY) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Bavarian Nordic A/S and Brainstorm Cell Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bavarian Nordic A/S	0	0	0	0	N/A
Brainstorm Cell Therapeutics	0	0	1	0	3.00

Given Brainstorm Cell Therapeutics’ higher possible upside, analysts clearly believe Brainstorm Cell Therapeutics is more favorable than Bavarian Nordic A/S.

Volatility and Risk

Bavarian Nordic A/S has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Insider & Institutional Ownership

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 5.5% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Bavarian Nordic A/S and Brainstorm Cell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bavarian Nordic A/S	14.74%	15.54%	10.90%
Brainstorm Cell Therapeutics	N/A	N/A	-431.16%

Valuation & Earnings

This table compares Bavarian Nordic A/S and Brainstorm Cell Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bavarian Nordic A/S	$1.02 billion	2.01	$214.20 million	$0.63	13.94
Brainstorm Cell Therapeutics	N/A	N/A	-$17.19 million	($0.32)	-1.25

Bavarian Nordic A/S has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Bavarian Nordic A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Bavarian Nordic A/S beats Brainstorm Cell Therapeutics on 8 of the 12 factors compared between the two stocks.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.